Unlocking the next generation of complement therapies
Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines targeting the classical complement pathway via C1q inhibition. Its pipeline addresses autoimmune, neurodegenerative, and ophthalmic disorders, with candidates including ANX005, ANX007, and ANX009 in clinical development. The company was founded in 2011 by Arnon Rosenthal and Ben Barres.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2025
Jun 2024
Jul 2020
Jul 2020
Dec 2018
Jun 2016
Dec 2014
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
